[Edaily Starin Gim Ga Yeong Reporter] Attention is focused on what story will unfold in the final episode of SBS’s “Chaebol X Detective 2.”
A preview for Episode 14, released on the 19th, hints at a whirlwind final showdown. With Yoo Seong-won’s (played by Yoo Seung-ho) basement completely burned down—reducing all evidence of the crime to ashes—and Park Jun-young (played by Kang Sang-jun) and Choi Kyung-jin (played by Kim Shin-bi), who were pursuing Yoo Seong-won as he fled, also getting into an accident, the Special Crimes Unit 1 has been completely dismantled. Joo Hye-ra (played by Jung Eun-chae) chases after Yoo Seong-won, seemingly gripped by madness, after leaving behind the words, “I’ll finish this.” However, the scene is shocking: a blood-soaked Yoo Seong-won is seen dragging someone’s body, while a battered and wounded Jin Yi-su (played by Ahn Bo-hyun) bursts into the exhibition hall. Amid a breathless standoff, tension mounts as Yoo Seong-won points a gun at Jin Yi-su. Jin Yi-su’s gaze, fixed on the rampaging Yoo Seong-won, is filled with more rage and a sense of justice than ever before. All eyes are on whether “Chaebol Detective” Jin Yi-su will be able to bring “the most notorious chaebol serial killer,” Yoo Seong-won, to justice. “Chaebol X Detective” is a drama that tells the story of Jin Yi-soo, a chaebol who becomes a detective. After Season 1 premiered in 2024, it garnered significant attention, and Season 2 was produced on the strength of its popularity. It began with a viewership rating of 6.1% (Nielsen Korea/nationwide households) for its first episode and reached a peak rating of 9.4% in its 13th episode. The finale will air on the 19th at 9:50 p.m.
This week (September 14–18), startups in various fields—including medical artificial intelligence (AI), content solutions, and content tech—secured investments from venture capital (VC) firms and acce…
“Building on our designation as an innovative medical device by the U.S. Food and Drug Administration (FDA), we plan to establish a local subsidiary within this year. Next year, we will launch laborat…
SK BIOPHARMACEUTICALS(326030)has drawn attention by repeatedly emphasizing that the deal to acquire “Opacalym” (BHV-7000), a new drug candidate for epilepsy, from the U.S. biotech company Biohaven is …